Compare DexCom, Inc. (DXCM) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Trade Desk Inc — how do they compare? DexCom, Inc. trades at $84 (market cap $31.86B), while Trade Desk Inc trades at $12.08 (market cap $5.83B). The key difference: DexCom, Inc. is far larger — about 5.5× Trade Desk Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Trade Desk Inc for 72 Days on average.
| DXCM | TTD | |
|---|---|---|
Market Cap | $31.86B | $5.83B |
Volume | 3,607,070 | 15,864,392 |
Sector | Health | Media |
52-Week High | $92.34 | $54.13 |
52-Week Low | $54.84 | $11.92 |
Typical Hold Time | 62 Days | 72 Days |
Enterprise Value | $31.32B | $4.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
The Trade Desk (TTD) trades at $12.08, down 0.12% on the day and showing bearish technical signals with mixed earnings performance. The company maintains strong profitability with 76.9% gross margins and 15.4% ROE, though revenue growth has slowed to 3% in 2026 projections. Recent news highlights competitive pressures from Amazon and Alphabet, with the stock down significantly from its 2024 peak.
While TTD's valuation appears attractive with low P/E and P/S ratios, investors face headwinds from slowing growth and intense competition. The consensus price target of $14.72 suggests moderate upside potential, but near-term catalysts appear limited as the company navigates market share challenges and workforce reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
